top of page

Janssen-Protagonist IL-23R Collaboration

Sexton Riley LLP Represents Janssen in Worldwide Exclusive License and Collaboration Agreement with Protagonist Therapeutics

May 2017

Sexton Riley LLP represented Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, in a worldwide exclusive license and collaboration agreement with Protagonist Therapeutics, Inc. (Protagonist) to develop, manufacture and commercialize PTG-200, a first-in-class, oral interleukin-23 receptor (IL-23R) antagonist drug candidate in development for the treatment of Crohn’s disease and ulcerative colitis (UC).

​The Janssen press release is here.


bottom of page